| A CFTR potentiator in patients with cystic fibrosis and the G551D mutation BW Ramsey, J Davies, NG McElvaney, E Tullis, SC Bell, P Dřevínek, ... New England Journal of Medicine 365 (18), 1663-1672, 2011 | 2395 | 2011 |
| Elexacaftor–tezacaftor–ivacaftor for cystic fibrosis with a single Phe508del allele PG Middleton, MA Mall, P Dřevínek, LC Lands, EF McKone, D Polineni, ... New England Journal of Medicine 381 (19), 1809-1819, 2019 | 1523 | 2019 |
| Lumacaftor–ivacaftor in patients with cystic fibrosis homozygous for Phe508del CFTR CE Wainwright, JS Elborn, BW Ramsey, G Marigowda, X Huang, M Cipolli, ... New England Journal of Medicine 373 (3), 220-231, 2015 | 1503 | 2015 |
| Efficacy and safety of the elexacaftor plus tezacaftor plus ivacaftor combination regimen in people with cystic fibrosis homozygous for the F508del mutation: a double-blind … HGM Heijerman, EF McKone, DG Downey, E Van Braeckel, SM Rowe, ... The Lancet 394 (10212), 1940-1948, 2019 | 994 | 2019 |
| The future of cystic fibrosis care: a global perspective SC Bell, MA Mall, H Gutierrez, M Macek, S Madge, JC Davies, PR Burgel, ... The Lancet Respiratory Medicine 8 (1), 65-124, 2020 | 775 | 2020 |
| Tezacaftor–ivacaftor in patients with cystic fibrosis homozygous for Phe508del JL Taylor-Cousar, A Munck, EF McKone, CK Van Der Ent, A Moeller, ... New england journal of medicine 377 (21), 2013-2023, 2017 | 773 | 2017 |
| VX-445–tezacaftor–ivacaftor in patients with cystic fibrosis and one or two Phe508del alleles D Keating, G Marigowda, L Burr, C Daines, MA Mall, EF McKone, ... New england journal of medicine 379 (17), 1612-1620, 2018 | 624 | 2018 |
| Effect of genotype on phenotype and mortality in cystic fibrosis: a retrospective cohort study EF McKone, SS Emerson, KL Edwards, ML Aitken The Lancet 361 (9370), 1671-1676, 2003 | 494 | 2003 |
| Restoring cystic fibrosis transmembrane conductance regulator function reduces airway bacteria and inflammation in people with cystic fibrosis and chronic lung infections KB Hisert, SL Heltshe, C Pope, P Jorth, X Wu, RM Edwards, M Radey, ... American journal of respiratory and critical care medicine 195 (12), 1617-1628, 2017 | 352 | 2017 |
| VX-659–tezacaftor–ivacaftor in patients with cystic fibrosis and one or two Phe508del alleles JC Davies, SM Moskowitz, C Brown, A Horsley, MA Mall, EF McKone, ... New england journal of medicine 379 (17), 1599-1611, 2018 | 340 | 2018 |
| Assessment of safety and efficacy of long-term treatment with combination lumacaftor and ivacaftor therapy in patients with cystic fibrosis homozygous for the F508del-CFTR … MW Konstan, EF McKone, RB Moss, G Marigowda, S Tian, D Waltz, ... The lancet Respiratory medicine 5 (2), 107-118, 2017 | 311 | 2017 |
| CFTR genotype as a predictor of prognosis in cystic fibrosis EF McKone, CH Goss, ML Aitken Chest 130 (5), 1441-1447, 2006 | 295 | 2006 |
| Sustained benefit from ivacaftor demonstrated by combining clinical trial and cystic fibrosis patient registry data GS Sawicki, EF McKone, DJ Pasta, SJ Millar, JS Wagener, CA Johnson, ... American journal of respiratory and critical care medicine 192 (7), 836-842, 2015 | 247 | 2015 |
| Long-term safety and efficacy of ivacaftor in patients with cystic fibrosis who have the Gly551Asp-CFTR mutation: a phase 3, open-label extension study (PERSIST) EF McKone, D Borowitz, P Drevinek, M Griese, MW Konstan, ... The lancet Respiratory medicine 2 (11), 902-910, 2014 | 236 | 2014 |
| Lung transplant referral for individuals with cystic fibrosis: Cystic Fibrosis Foundation consensus guidelines KJ Ramos, PJ Smith, EF McKone, JM Pilewski, A Lucy, SE Hempstead, ... Journal of Cystic Fibrosis 18 (3), 321-333, 2019 | 190 | 2019 |
| Delayed neutrophil apoptosis enhances NET formation in cystic fibrosis RD Gray, G Hardisty, KH Regan, M Smith, CT Robb, R Duffin, A Mackellar, ... Thorax 73 (2), 134-144, 2018 | 188 | 2018 |
| Triple Therapy for Cystic Fibrosis Phe508del–Gating and –Residual Function Genotypes PJ Barry, MA Mall, A Álvarez, C Colombo, KM de Winter-De Groot, I Fajac, ... New England Journal of Medicine 385 (9), 815-825, 2021 | 180 | 2021 |
| A Phase 3 Open-Label Study of Elexacaftor/Tezacaftor/Ivacaftor in Children 6 through 11 Years of Age with Cystic Fibrosis and at Least One F508del Allele ET Zemanick, JL Taylor-Cousar, J Davies, RL Gibson, MA Mall, ... American journal of respiratory and critical care medicine 203 (12), 1522-1532, 2021 | 179 | 2021 |
| Ambient air pollution, lung function, and airway responsiveness in asthmatic children D Ierodiakonou, A Zanobetti, BA Coull, S Melly, DS Postma, HM Boezen, ... Journal of allergy and clinical immunology 137 (2), 390-399, 2016 | 162 | 2016 |
| A multinational report to characterise SARS-CoV-2 infection in people with cystic fibrosis R Cosgriff, S Ahern, SC Bell, K Brownlee, PR Burgel, C Byrnes, H Corvol, ... Journal of cystic fibrosis 19 (3), 355-358, 2020 | 147 | 2020 |
